Nexentis Announces Reverse Stock Split

Outstanding options and warrants will receive proportionate adjustments to exercise prices and the number of shares issuable.

Rhea-AI Summary

Nexentis Technologies (NXTS) approved a 1-for-5 reverse stock split scheduled to take effect for Nasdaq purposes on November 9, 2026.

Split-adjusted trading will begin that day on the Nasdaq Capital Market under the unchanged symbol NXTS. Every five outstanding common shares will become one share, reducing outstanding shares from approximately 2.9 million to approximately 600 thousand. Authorized common shares will remain unchanged. The company gives regaining compliance with Nasdaq’s continued listing requirements and attracting certain institutional investors as reasons for the reverse split authorization.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.1-for-5 reverse split addresses the company’s stated goal of regaining compliance with Nasdaq’s continued listing requirements.

News Explained

When the approved 1-for-5 split takes effect November 9, outstanding options and warrants will also have their exercise prices and issuable share counts adjusted proportionately alongside the common-share consolidation.

Key Figures

Reverse split ratio: 1-for-5 Effective date: November 9, 2026

Reverse split ratio

1-for-5

Each 5 outstanding shares convert to 1 share

Effective date

November 9, 2026

Scheduled effective date for Nasdaq purposes

Key Terms

reverse stock split, cusip, warrants, fractional shares

4 terms

reverse stock split financial

"approved a one-for-five (1-for-5) reverse stock split of its common stock"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

cusip technical

"under a new CUSIP number 80512Q709"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

warrants financial

"all outstanding options and warrants entitling the holders to purchase common stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

fractional shares financial

"No fractional shares will be issued if, as a result of the reverse stock split"

Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ness Ziona, Israel, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, announced that its Board of Directors has approved a one-for-five (1-for-5) reverse stock split of its common stock that is scheduled to become effective for Nasdaq purposes on November 9, 2026. Beginning on November 9, 2026, the Company’s common stock will trade on the Nasdaq Capital Market on a split adjusted basis under a new CUSIP number 80512Q709. The Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “NXTS.” As previously disclosed, at the Special Meeting of the Stockholders of Nexentis held on April 30, 2026, the Company’s stockholders approved a proposal authorizing the Company’s Board of Directors, among other things, to effect one or more reverse stock splits at a ratio of not less than 1-for-2 and not more than 1-for-500 in order to increase the per share price and bid price of the Company’s common stock to regain compliance with the continued listing requirements of Nasdaq and make the common stock more attractive to certain institutional investors, which would provide for a stronger investor base.

Upon effectiveness of the reverse stock split, every 5 shares of the Company’s outstanding common stock will be converted to one share of common stock. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options and warrants entitling the holders to purchase common stock.

No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would otherwise become entitled to a fractional share because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, each such stockholder will automatically be entitled to receive an additional fraction of a share of common stock to round up to the next whole share. The number of authorized shares of the Company’s common stock will not change, while the number of outstanding shares will be reduced from approximately 2.9 million to approximately 600 thousand.

Registered stockholders holding their shares of common stock in book-entry or through a bank, broker or other nominee form do not need to take any action in connection with the reverse stock split. For those stockholders holding physical stock certificates, the Company’s transfer agent, Securities Transfer Corporation, will send instructions for exchanging those certificates for new certificates representing the post-split number of shares. Securities Transfer Corporation can be reached at (469) 633-0101.

Additional information about the reverse stock split can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 12, 2026, a copy of which is also available at www.sec.gov or at https://nexentistech.com/sec-filings/.

About Nexentis Technologies Inc.

Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd., a drug-discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

For additional details, please visit https://nexentistech.com/

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties. Actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including market conditions as well as those discussed under the heading “Risk Factors” in Nexentis’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026, and in any subsequent filings with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contacts:

Michal Efraty
michal@efraty.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Nexentis’s reverse stock split take effect, and what is the ratio?

Nexentis’s 1-for-5 reverse stock split is scheduled to become effective for Nasdaq purposes on November 9, 2026. Split-adjusted trading will begin that day on the Nasdaq Capital Market, with the trading symbol remaining NXTS.

Do Nexentis shareholders need to take action for the reverse stock split?

Shareholders holding shares in book-entry form or through a bank, broker or other nominee do not need to take action. Holders of physical stock certificates will receive instructions from Securities Transfer Corporation for exchanging them for certificates representing the post-split share count.

How will Nexentis handle fractional shares in the reverse stock split?

Nexentis will round up to the next whole share rather than issue fractional shares. A shareholder whose holdings are not evenly divisible by the split ratio will automatically receive the additional fraction needed to reach a whole share.